AbbVie

Open: 144.48 Close: 148.85 Change: 4.37

An AI to read internet: The best strategy to evaluate AbbVie Company Inc Stock.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, link, year, Abbvie, earnings, share, quarter, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

RINVOQ is a selective JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. European Medicines Agencies Committee for Medicinal Products for Human Use adopts positive opinion for epcoritamab (tepkinly®) European Commission decision on this indication is anticipated later this year.

Today's News

European Medicines Agencies Committee for Medicinal Products for Human Use adopts positive opinion for epcoritamab (tepkinly®) for the treatment of adults with relapsed/refractory diffuse large b-cell lymphoma (DLBCL) The final European Commission decision on this indication is anticipated later this year. The Yes link below will take you out of the AbbVie family of websites. The inclusion of any link does not imply endorsement of the linked site by Abbvie. RINVOQ is a selective JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. AbbVie raised its annual profit forecast to $10.90 to $11.10 per share after beating analysts estimates for second-quarter earnings. Shares surged 5.3% to $149.41. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. The Abbvie Press Kit is designed to provide journalists with a broad range of background information. The Yes link below will take you out of the AbbVie family of websites. The inclusion of any link does not imply endorsement of the linked sites. AbbVie raising its adjusted diluted EPS guidance for the full year 2023 from $10.62 - $11.02 to $10.72 -  $11.12. AbbVie expects full-year earnings in the range of $10.90 to $11.10 per share. Abbvie shares have declined 12% since the beginning of the year. Abvie is providing these links to you only as a convenience. AbbVies Skyrizi Superior to Amgen Plaque Psoriasis Drug, Study says. Research discovered no new safety signals. AbbVie reported Q1 2023 earnings per share (EPS) of $0.13 , missing estimates of $2.51 by 94.88%. In the same quarter last year, Abbvie s earnings per quarter was $2. AbbVie Forward-Looking Statements are subject to risks and uncertainties that may cause actual results to differ from those expressed or implied in the forward-looking statements. There is no split for Abbvie (ABBVie) due to the upcoming split. AbbVie announces financial results for the second quarter ended June 30, 2023. The company will announce its second-quarter 2023 financial results on Thursday, July 27. How AbbVies Humira Still Reigns, Despite New Competition. Revenue for blockbuster arthritis drug declined in the second quarter, largely due to discounts. AbbVie will announce its second-quarter 2023 financial results on Thursday, July 27, 2023. The company will host a live webcast of the earnings conference call at 8 a.m. It will be accessible through the Investor Relations website.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, link, year, Abbvie, earnings, share, quarter, and the most common words in the summary are: abbvie, stock, news, abbv, earnings, report, dividend, . One of the sentences in the summary was: European Medicines Agencies Committee for Medicinal Products for Human Use adopts positive opinion for epcoritamab (tepkinly®) European Commission decision on this indication is anticipated later this year.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #news #abbv #earnings #report #dividend.